A randomized, double-blind, placebo-controlled study of B-cell lymphoma 2 homology 3 mimetic gossypol combined with docetaxel and cisplatin for advanced non-small cell lung cancer with high expression of apurinic/apyrimidinic endonuclease 1

Background Overexpression of apurinic/apyrimidinic endonuclease 1 (APE1) is an important cause of poor chemotherapeutic efficacy in advanced non-small cell lung cancer (NSCLC) patients. Gossypol, a new inhibitor of APE1, in combination with docetaxel and cisplatin is believed to improve the efficacy...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Invest New Drugs
Päätekijät: Wang, Yuxiao, Li, Xuemei, Zhang, Liang, Li, Mengxia, Dai, Nan, Luo, Hao, Shan, Jinlu, Yang, Xueqin, Xu, Mingfang, Feng, Yan, Xu, Chengxiong, Qian, Chengyuan, Wang, Dong
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Springer US 2020
Aiheet:
Phase II Studies
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7575477/
https://ncbi.nlm.nih.gov/pubmed/32529467
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-020-00927-0
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia